| HOME >> MEDICINE >> TECHNOLOGY |
$
4,940Non-cash charges48,641
48,424Changes in assets and liabilities5,130
(10,088)Tax benefit from exercises of stock options and vesting of restricted stock units(14,009)
(13,293)Net cash provided by operating activities163,518
129,983Investing:Cash Flows from Investing Activities:Purchases of property and equipment(39,927)
(28,646)Proceeds from disposition of pharmaceutical product lines3,000
-Proceeds from sale of property and equipment223
86Acquisitions of intangible assets and a business, net of cash acquired (2,600)
(244)Net cash used by investing activities(39,304)
(28,804)Financing:Cash Flows from Financing Activities:Borrowings on revolving credit facilities, net24,903
7,135Payment of notes payable(643)
(605)Repurchases of common stock(166,016)
(117,157)Proceeds from the exercise of stock options and employee stock purchase plans26,080
22,055Tax benefit from exercises of stock options and vesting of restricted stock units14,009
13,293Net cash used by financing activities(101,667)
(75,279)Net effect of changes in exchange rates on cash2,037
884Net increase in cash and cash equivalents24,584
26,784Cash and cash equivalents, beginning of period156,915
106,728Cash and cash equivalents, end of period$
81,499
$
33,512IDEXX Laboratories, Inc. and SubsidiariesFree Cash FlowAmounts in thousands (Unaudited)Nine Months EndedSept. 30,Sept. 30,20112010Free Cash Flow:Net cash provided by operating activities$
3,518
$
29,983Financing cash flows attributable to tax benefits from exercise of stock options and vesting of restricted stock units14,009
| SOURCE IDEXX Laboratories, Inc. Copyright©2010 PR Newswire. All rights reserved |